Initial multicentre experience of 68 gallium-PSMA PET/CT guided robot-assisted salvage lymphadenectomy: acceptable safety profile but oncological benefit appears limited.
Amila R SiriwardanaJames ThompsonPim J van LeeuwenShaela DoigAnton KalsbeekLouise EmmettWarick DelpradoDavid WongHemamali SamaratungaAnne-Maree HaynesGeoff CoughlinPhillip StrickerPublished in: BJU international (2017)
Although RASND appears safe and feasible, less than half of our cohort had a treatment response, and less than a quarter experienced BCR-free survival at 12-month median follow-up. 68 Ga-PSMA imaging underestimates micro-metastatic disease, therefore RASND will rarely be curative. Strict patient selection and restricting RASND to clinical trials is recommended. Long-term follow-up from such trials is required to further assess potential quality of life and mortality benefits.
Keyphrases
- pet ct
- robot assisted
- free survival
- clinical trial
- minimally invasive
- high resolution
- acute lymphoblastic leukemia
- small cell lung cancer
- squamous cell carcinoma
- positron emission tomography
- case report
- cardiovascular events
- rectal cancer
- study protocol
- tyrosine kinase
- double blind
- phase ii
- risk factors
- chronic myeloid leukemia
- cross sectional
- prognostic factors
- human health
- phase iii
- cardiovascular disease
- lymph node
- radiation therapy
- locally advanced
- lymph node metastasis
- neoadjuvant chemotherapy
- sentinel lymph node